Scarica l'app Stockscreener
0.3574
2.55%
0.0089
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Pharmacyte Biotech Inc Borsa (PMCB) Ultime notizie
Is PharmaCyte Biotech (NASDAQ:PMCB) Stock Worth Watching Today? - kalkinemedia.com
Could PharmaCyte Biotech (NASDAQ:PMCB) Shift the Penny Stocks Story? - kalkinemedia.com
PharmaCyte (NASDAQ: PMCB) risks delisting if its stock stays below $1 - Stock Titan
PharmaCyte Biotech Inc (PMCB) Key Financial Ratios – Valuation, Profitability & More - Value Research
PharmaCyte Biotech Inc (PMCB) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
PharmaCyte Biotech Inc (PMCB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
PharmaCyte Biotech (NASDAQ: PMCB): Why Is A scheduled reporting event in Focus Now? - Kalkine Media
PMCBPharmaCyte Biotech Inc Forecast, Target Price - Finviz
PharmaCyte (PMCB) Financial Results: The Company Lists Its Latest Available Figures in the Current Update; Market Reaction: Shares Move 1.58% HigherQuarterly Profit Report - vinanet.vn
PharmaCyte (PMCB) Share-Price Review: Slides 4.80% to $0.52 at the Close; Technical Focus: Price Remains Between $0.49 Support and $0.55 Resistance in the Current UpdateEarnings Miss Risk - vinanet.vn
PMCB Q1 2026 Earnings: Clinical-Stage Biotech Posts -$0.09 EPS with No RevenueSegment Revenue Breakdown - vinanet.vn
PharmaCyte Biotech (PMCB) Climbs to $0.55 as Micro-Cap Biotech Holds Key SupportFundamentals - dars.gov.et
PharmaCyte Biotech (PMCB) Climbs to $0.55 as Micro-Cap Biotech Holds Key SupportEarnings Breakout Stocks - vinanet.vn
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PharmaCyte Biotech Inc (PMCB) Stock News Today - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.59 as Shares Dip 0.71%Change of Character - vinanet.vn
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Clinical ProgressHealthcare Earnings Report - dars.gov.et
PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary - TradingView
PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Institutional Confidence - TradingKey
PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
PharmaCyte Biotech Inc (PMCB) Balance Sheet - TradingKey
PharmaCyte Biotech Inc (PMCB) Cash Flow - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.600|Chg%:-0.005 - TradingKey
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Income Statement - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.576|Chg%:-0.024 - tradingkey.com
PMCB|PharmaCyte Biotech Inc|Price:0.611|Chg%:+0.035 - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.57 Support Amid Minimal Price MovementSMA Signal - vinanet.vn
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Revenue-less Biotech Posts Net Loss; Stock SlipsEarnings Revision Report - vinanet.vn
PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech (PMCB) Edges Lower Near Support; Key Levels in FocusLong Short Pair - vinanet.vn
PMCB Q1 2026 Earnings: Continued Development Costs Weigh on Results, No Revenue ReportedEarnings Season Outlook - vinanet.vn
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60Andrews Pitchfork - dars.gov.et
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60Island Reversal - careplusvn.com
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN - Moomoo
PharmaCyte Biotech (PMCB) Faces Near-Term Pressure, Testing Key Support at $0.60Tick Index - vinanet.vn
[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity - Stock Titan
PharmaCyte Biotech (PMCB) cancels erroneous stock option grant - Stock Titan
PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant - Stock Titan
PharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option grant - Stock Titan
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsDebt Free Companies - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsBox Spread - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsIceberg Order - vinanet.vn
PharmaCyte Biotech (PMCB) Slides 1.4% Near Key Support Level at $0.66Adaptive Moving Average - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader ConvictionGap Down Bounce Plays - dars.gov.et
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):